Abcuro Patent Portfolio Analysis

Sixty-six million arrives, six years in

RA Capital Management, BlackRock and New Enterprise Associates put $66M into a Series D. That is late-stage money from investors who read filing histories before they wire. Abcuro was founded in 2015. The first patent family did not appear until 2019. Four years of work preceded the first claim the company was willing to commit to paper, which is either patience or the length of time it took to find the target.

The three most recent filing titles say what the money is buying: treating T-cell large granular lymphocytic leukemia, treating inclusion body myositis, and depleting T cells that express KLRG1. Two indications and one mechanism. The mechanism title is the one that carries weight, because it is written around a receptor rather than a disease. Indications multiply. A receptor claim does not need to.

One granted ribbon, six still open

Seven families. One granted. Six published and pending, with the first of those close enough to grant that the ratio could change without warning. The skew is the honest picture of a company that started filing in 2019 and has not stopped. Nothing about it is unusual for the age. What it does mean is that most of Abcuro's paper position is still a proposal rather than a right.

The granted family is the exception, and it is enforceable today. That single fact carries disproportionate weight in a field where claim scope decides everything. Filings across AU, EP, IL, MX and WO show an intention to hold the position in multiple jurisdictions rather than the United States alone. The velocity tells its own story: one, one, nothing, three, nothing, nothing, two. Bursts, not a drumbeat.

Most of the position is still a proposal rather than a right.

Thirteen names, one on nearly everything

Thirteen inventors across seven families. Stefano Gulla appears on five of them. Kenneth Evan Thompson appears on four. That is a concentrated authorship pattern: two people whose names run through most of the record, and a wider group that appears once or twice around specific families. It reads like a small core with the mechanism in their heads and collaborators pulled in per indication.

Concentration of this kind is informative in both directions. It means the technical thread is coherent, that the 2019 filing and the 2025 filings were shaped by the same understanding. It also means the institutional memory of why each claim was drafted the way it was sits with very few people. For a portfolio whose value depends on scope rather than count, that is worth knowing.

Six giants and a dot, same groups

The claims cluster in C07K: peptides and antibodies. Over the last five years the same CPC groups drew Regeneron Pharma with 351 families, Hoffmann La Roche with 306, Genentech with 271, Janssen Biotech with 261, Amgen with 206 and Novartis with 195. Abcuro has seven. On the same scale the difference is not a gap, it is a category change.

Count is the wrong measure here and the picture makes that obvious. Nobody out-files Regeneron in antibody space. What a seven-family portfolio can do is be specific: written around one receptor, in defined indications, with a priority date in 2019. Crowded art raises the bar for scope and lowers the value of volume. The relevant question is whether the granted claims describe something the 1,590 families around them do not.

Nobody out-files Regeneron in antibody space.

Two hospitals reading the same file

Brigham and Womens Hospital cites Abcuro's work in five publications. National Jewish Health cites it in two. Seven citations is a small number in absolute terms, but the sources matter more than the volume. These are clinical research institutions, not competing filers building around a position. They are reading the mechanism because it is relevant to what they are studying.

Academic citation is the earliest external evidence that a claim describes something real. It arrives before revenue, before approval, sometimes before the patent grants. Both citing organizations sit in the disease space the filing titles name. For a portfolio still six-sevenths pending, this is the closest thing to independent confirmation that the target was chosen well rather than chosen conveniently.

What the hiring plan already answered

Thirty open roles. Ten in bio and clinical, five in hardware, four in operations and finance, one in go-to-market, ten uncategorised. The named positions are CMC purification process development, CMC cell culture manufacturing, analytical development and QA compliance. That is a manufacturing and quality build, not a discovery build. A company hiring purification and cell culture leads has decided what molecule it is making.

So the shape is settled. Same claim space, more filings, and a hiring plan that matches the filings rather than diverging from them. The moat is thin by count and real by construction: one enforceable family today, six more in flight, a 2019 priority date on a receptor-level mechanism, and two clinical institutions already building on it. Everything now turns on scope.